中华医学杂志（英文版）Issue(21)：3718-3723,6.DOI:10.3760/cma.j.issn.0366-6999.20140627
Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis
Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis
Feng Xuebing 1Gu Fei 1Chen Weiwei 1Liu Yan 2Wei Hua 3Liu Lin 4Yin Songlou5
作者信息
- 1. Department of Rheumatology and Immunology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing,Jiangsu 210008, China
- 2. Department of Rheumatology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, China
- 3. Department of Rheumatology and Immunology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, China
- 4. Department of Rheumatology and Immunology, Central Hospital of Xuzhou City, Xuzhou, Jiangsu 221009, China
- 5. Department of Rheumatology and Immunology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, China
- 折叠
摘要
关键词
mizoribine/ mycophenolate mofetil/ cyclophosphamide/ lupus nephritisKey words
mizoribine/ mycophenolate mofetil/ cyclophosphamide/ lupus nephritis引用本文复制引用
Feng Xuebing,Gu Fei,Chen Weiwei,Liu Yan,Wei Hua,Liu Lin,Yin Songlou..Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis[J].中华医学杂志（英文版）,2014,(21):3718-3723,6.
